NCT06529146View on ClinicalTrials.gov

Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural History Control

Active, not recruitingOBSERVATIONAL
Enrollment

909

Participants

Timeline

Start Date

March 18, 2019

Primary Completion Date

September 6, 2024

Study Completion Date

January 31, 2026

Conditions
Spinocerebellar Ataxias
Interventions
DRUG

BHV-4157

BHV-4157 (troriluzole) 200 mg QD

Trial Locations (1)

06510

Biohaven, New Haven

Sponsors
All Listed Sponsors
lead

Biohaven Therapeutics Ltd.

INDUSTRY

NCT06529146 - Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural History Control | Biotech Hunter | Biotech Hunter